Education
About Us
Working with TipRanks
Follow Us
Gemina Laboratories Ltd. (TSE:GLAB)
:GLAB
GLAB Stock Chart & Stats
C$0.06
-C$0.02(-2.86%)
At close: 4:00 PM EST
C$0.06
-C$0.02(-2.86%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$1.25
Previous CloseN/A
Volume500.00
Average Volume (3M)13.56K
Market Cap
C$3.06M
Enterprise ValueC$4.83M
Total Cash (Recent Filing)-C$613.00
Total Debt (Recent Filing)C$240.11K
Price to Earnings (P/E)―
Beta-0.76
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding76,570,910
10 Day Avg. Volume19,305
30 Day Avg. Volume13,558
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-9.02
Price to Sales (P/S)0.00
P/FCF Ratio-30.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationA move from persistent cash burn to slight positive operating and free cash flow reflects operational improvement versus prior years. If sustained, even modest positive cash generation reduces near-term financing urgency and extends runway, improving strategic flexibility for R&D or commercialization steps.
Modest Absolute Debt LoadLow nominal debt limits fixed interest obligations and reduces near-term default risk relative to heavily leveraged peers. This weaker leverage footprint preserves optionality for funding via debt or equity and gives management more capacity to prioritize R&D or product development without large mandatory cash outflows.
Shrinking Reported LossesA reduction in the trailing loss versus prior annual results signals progress toward cost control or transitional revenue recognition. For an early-stage biotech, shrinking losses improve runway visibility, reduce frequency/size of financing needs, and can increase investor willingness to support next development milestones.
Bears Say
Minimal Recurring RevenueThe company lacks meaningful product or service revenue and reports negative gross profit, which undermines proof of commercial traction. Without scalable revenue, the business must rely on financing for operations, making durable margin improvement and self-funded growth unlikely absent material commercial progress.
Negative Shareholder EquityAn accumulated deficit that produces negative equity signals long-standing losses have exhausted capital reserves. This constrains strategic options, increases insolvency and covenant risks, and raises the probability of dilutive financings or balance-sheet restructuring to restore solvency and fund ongoing R&D.
Fragile Cash-flow ImprovementThe positive operating/free cash flow figures are tiny relative to the multi-million net loss, so cash-generation gains may not be durable. Continued R&D and operating needs likely require fresh capital, leaving the company exposed to execution risk, dilution pressure, and potential interruptions if funding windows close.
Gemina Laboratories Ltd. News
GLAB FAQ
What was Gemina Laboratories Ltd.’s price range in the past 12 months?
Gemina Laboratories Ltd. lowest stock price was C$0.03 and its highest was C$1.25 in the past 12 months.
What is Gemina Laboratories Ltd.’s market cap?
Gemina Laboratories Ltd.’s market cap is C$3.06M.
When is Gemina Laboratories Ltd.’s upcoming earnings report date?
Gemina Laboratories Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 78 days.
How were Gemina Laboratories Ltd.’s earnings last quarter?
Gemina Laboratories Ltd. released its earnings results on Dec 30, 2025. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is Gemina Laboratories Ltd. overvalued?
According to Wall Street analysts Gemina Laboratories Ltd.’s price is currently Overvalued.
Does Gemina Laboratories Ltd. pay dividends?
Gemina Laboratories Ltd. does not currently pay dividends.
What is Gemina Laboratories Ltd.’s EPS estimate?
Gemina Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gemina Laboratories Ltd. have?
Gemina Laboratories Ltd. has 76,570,910 shares outstanding.
What happened to Gemina Laboratories Ltd.’s price movement after its last earnings report?
Gemina Laboratories Ltd. reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -40%.
Which hedge fund is a major shareholder of Gemina Laboratories Ltd.?
Currently, no hedge funds are holding shares in TSE:GLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gemina Laboratories Ltd.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
Technical Analysis
Restart Life Sciences
―
Entheon Biomedical
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Doseology Sciences
―